콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

05-636-AF488

Sigma-Aldrich

Anti-phospho Histone H2A.X (Ser139), clone JBW301, Alexa Fluor 488 Conjugate Antibody

clone JBW301, from mouse, ALEXA FLUOR 488

동의어(들):

Histone H2AX, H2a/x, Histone H2A.X

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
eCl@ss:
32160702
NACRES:
NA.41

생물학적 소스

mouse

Quality Level

결합

ALEXA FLUOR 488

항체 형태

purified antibody

항체 생산 유형

primary antibodies

클론

JBW301, monoclonal

종 반응성

human

종 반응성(상동성에 의해 예측)

vertebrates (based on 100% sequence homology)

기술

immunocytochemistry: suitable

동형

IgG1

NCBI 수납 번호

UniProt 수납 번호

배송 상태

wet ice

타겟 번역 후 변형

phosphorylation (pSer139)

유전자 정보

human ... H2AX(3014)

일반 설명

Histone H2A.X is a variant of histone H2A, and is similarly associated with genomic DNA. However, histone is structurally different from other members of the H2A family in possessing a C-terminal tail that contains the Ser139 residue that is phosphorylated in response to breaks in double-stranded DNA. The phosphorylation of H2A.X is a rapid process that is mediated by ATM/ATR proteins.

애플리케이션

This Anti-phospho Histone H2A.X (Ser139) antibody, clone JBW301, Alexa Fluor 488 Conjugate is validated for use in ICC for the detection of phospho Histone H2A.X (Ser139).

품질

Evaluated by Immunocytochemistry in untreated (negative control) and Staurosporin treated HeLa cells.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected phospho-Histone H2A.X (Ser139) in Staurosporin treated HeLa cells, and not in untreated HeLa cells.

표적 설명

17 kDa calculated

기타 정보

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

법적 정보

ALEXA FLUOR is a trademark of Life Technologies

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Huan Zhang et al.
Frontiers in oncology, 12, 999302-999302 (2022-12-17)
Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms
Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Jolien Van den Bossche et al.
Cancers, 11(12) (2019-12-05)
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in vitro therapeutic effects of volasertib, a Plk1 inhibitor, in combination
Lidia F Hernandez et al.
Cell death discovery, 7(1), 134-134 (2021-06-06)
Ovarian cancer is the most lethal gynecological cancer in the US. Standard treatment consists of surgery followed by chemotherapies relying on apoptotic tumor cell death. Most women with advanced stage disease will relapse, suggesting that this disease is characterized by
Michelle Ricoul et al.
Cancers, 11(9) (2019-09-25)
Many toxic agents can cause DNA double strand breaks (DSBs), which are in most cases quickly repaired by the cellular machinery. Using ionising radiation, we explored the kinetics of DNA lesion signaling and structural chromosome aberration formation at the intra-

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.